Skip to main content

Table 2 Multivariate Cox proportional hazards analysis for associations between covariates and survival endpoints

From: Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy

Covariate Hazard ratio (95 % confidence interval) P-value
Biochemical failure-free survival
Gleason sum 9 or 10 3.33 (1.62 – 6.85) 0.001
Clinical stage T3b/T4 2.17 (1.11 – 4.22) 0.02
Relapse-free survival
Gleason sum 9 or 10 4.43 (2.14 – 9.14) <0.001
Prostate cancer-specific survival
Gleason sum 9 or 10 4.13 (0.87 – 19.58) 0.07
Duration of ADT ≥28 months 0.20 (0.05 – 0.81) 0.02
Overall survival
Age ≥65 years 3.57 (1.00 – 12.82) 0.05
Gleason 4 + 3 17.26 (1.11 – 268.69) 0.04
Gleason 4 + 4 14.67 (1.07 – 200.81) 0.04
Gleason sum 9 or 10 70.11 (3.49 – 1407.99) 0.005
Duration of ADT ≥28 months 0.15 (0.05 – 0.44) 0.001
  1. Multivariable models adjusted for age at diagnosis, pre-treatment PSA, biopsy Gleason score, clinical stage, lymph node involvement, and duration of administration of ADT
  2. Abbreviations: androgen deprivation therapy (ADT)
  3. Threshold of p < 0.25 was used to exclude covariates from the final multivariable model, using backwards elimination